Policy, Biotech Chris Morrison Policy, Biotech Chris Morrison

Navigating a storm that threatens American biotechnology

Over the past four decades, David Beier has observed and participated in the evolution of the US biotechnology industry for several key vantage points. The industry’s success and freedom to innovate, he says, has been underpinned by – and helped create – a marketplace that was open enough to fully reward risk-taking investors devoting capital to cutting edge science. Today, that success faces new threats.

Read More
Policy, Culture, Biotech Jessica Sagers Policy, Culture, Biotech Jessica Sagers

Muckrakers, a righteous senator, and a gene therapy walk into a bar

Ah, the American Old West. Where the buffalo roamed, cowboys fought, and Coke still had cocaine. A LOT of things had cocaine. Only the most vigilant and educated physician or pharmacist could hope to keep harmful or useless drugs off their shelves. And if we can still find physicians prescribing ivermectin for COVID today, imagine how hard finding reliable information must have been back then. 

Read More